Sulfoxides
TARGETMOL CHEMICALS INC GSK2983559 ACTIVE METABO 10MG
Also available in 1 mg 5 mg 25 mg 50 mg 100 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. GSK2983559 active metabolite (RIPK2-IN-1) is a potent selective receptor-interacting protein-2 (RIP2) kinase inhibitor. purity: 98%
Medchemexpress LLC 4-(3,4-dihydroisoquinolin-2(1H)-yl)-2-(pyridin-3-yl)quinazoline | 796079-91-9 | 97.0% | 338.41 g/mol | C22H18N4 | 10 MG
GCase modulator-1 (compound 9g) is a quinazoline-derivative small molecule reported to modulate glucocerebrosidase (GCase) activity (reported AC50 = 2.23 μM). It is supplied as a research-grade powder for use in biochemical assays and in vitro studies; reported molecular weight is 338.41 g/mol and reported purity is ~97%.
- Modulates GCase (glucosidase) with reported AC50 = 2.23 μM.
- Quinazoline-derived small-molecule scaffold suitable for biochemical studies.
- Provided as a powder for preparation of assay solutions.
- Reported purity approximately 97% and molecular weight 338.41 g/mol.
- Intended for research use in vitro; not for human or clinical use.
Sigma Aldrich Fine Chemicals Biosciences Methyl sulfoxide >=99%, FG | 67-68-5 | MFCD00002089 | 10KG
Methyl sulfoxide >=99%, FG | Purity: >=99% | Mol Wt: 78.13 | 67-68-5 | MFCD00002089 | 10KG
Sigma Aldrich Fine Chemicals Biosciences Methyl sulfoxide >=99%, FG | 67-68-5 | MFCD00002089 | 25KG
Methyl sulfoxide >=99%, FG | Purity: >=99% | Mol Wt: 78.13 | 67-68-5 | MFCD00002089 | 25KG
Medchemexpress LLC CB2R/FAAH modulator-3 | 2876918-67-9 | 99.7% | 341.49 g·mol⁻¹ | C22H31NO2 | 10 MG
CB2R/FAAH modulator-3 is a small-molecule research compound that functions as a cannabinoid receptor 2 (CB2R) agonist and a fatty acid amide hydrolase (FAAH) inhibitor. Reported activity includes CB2R Ki = 20.1 nM, CB1R Ki = 67.6 nM, and FAAH IC50 = 3.4 μM. It is intended for preclinical studies of inflammatory signaling, neurodegeneration, cancer-related pathways, and infection-associated inflammatory responses.
- Dual activity as CB2R agonist and FAAH inhibitor.
- Reported high CB2R affinity (low nanomolar Ki).
- Lower affinity for CB1R supporting receptor selectivity.
- Applicable to studies of inflammation, neurodegeneration, and cancer biology.
- High chemical purity suitable for research use.
- Available in small-mass and solution formats for assay workflows.